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Differential Effects of Angiotensin
Converting Enzyme Inhibition and Diuretic
Therapy on Reductions in Ambulatory Blood
Pressure, Left Ventricular Mass, and
Vascular Hypertrophy
Mary J. Roman, Michael H. Alderman, Thomas G. Pickering, Riccardo Pini, James O. Keating,
Jean E. Sealey, and Richard B. Devereux
Diuretic-based therapy is less effective in reducing
the cardiac complications of hypertension than the
risk of stroke and may be less effective in reducing
left ventricular (LV) mass than is therapy with
angiotensin converting enzyme (ACE) inhibition. In
view of the strong association of LV hypertrophy
with cardiovascular risk, this study was designed to
compare the impact of therapy with a diuretic and
ACE inhibition on cardiac and vascular structure.
Fifty essential hypertensives (74% male, 88%
nonwhite) participated in a double-blind study for 6
months and were randomized to either ramipril or
hydrochlorothiazide (HCTZ). Echocardiography,
carotid ultrasonography, and ambulatory blood
pressure (BP) monitoring were performed at baseline
and 3 and 6 months after initiation of therapy. The
22 ramipril patients were comparable to the 28 HCTZ
patients at baseline in age, race, and 24-h BP.
Although HCTZ resulted in a greater reduction in
24-h BP, only treatment with ramipril resulted in a
decrease in LV mass (193 to 179 g, P < .005, v 184 to
182 g, P 5 NS), attributable to a reduction in wall
thicknesses but not in chamber diameter. In
multivariate analysis, both change in BP and
treatment group were independent predictors of
change in LV mass. Importantly, although neither
drug reduced carotid artery cross-sectional area,
relative wall thickness increased due to a tendency
for vessel diameter to decrease and wall thickness to
increase, particularly in the diuretic group. Ramipril
caused a sustained fall in plasma angiotensin II,
whereas HCTZ increased angiotensin II levels.
Although diuretic therapy was more effective in
lowering ambulatory BP in this predominantly
nonwhite population, only therapy with ACE
inhibition was associated with regression of LV
mass. Vascular geometry was altered consistent
with the reduction in distending pressure resulting
in vascular remodelling. Am J Hypertens 1998;
11:387–396 © 1998 American Journal of
Hypertension, Ltd.
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Diuretic-based regimens for the treatmentof hypertension reduce blood pressureand reduce overall cardiovascular diseaseevent rates in hypertensive patients com-
pared to placebo. However, this benefit has been es-
pecially due to stroke prevention, and results with
regard to prevention of cardiac complications of hy-
pertension have been less impressive.1,2 Although
metabolic side effects of diuretics have been impli-
cated, one potentially cardiotoxic action of these
agents that has received relatively little attention is
their activation of the renin-angiotensin system. Low
renin activity has been associated with a low preva-
lence of hypertensive complications,3 whereas high
renin status as well as augmentation of plasma renin
activity by a low-salt diet have been shown to predict
myocardial infarction independently of blood pres-
sure or other risk factors in hypertensive patients.4–6
Left ventricular mass is a stronger predictor of mor-
bid and mortal complications of hypertension than
blood pressure or all other risk factors except age
itself7–11 and the data, mostly from short-term and
small-sized studies, suggest that antirenin system
therapy with angiotensin converting enzyme (ACE)
inhibitors may reduce left ventricular mass more than
expected for the degree of blood pressure lowering in
hypertensive patients,12–15 animals,16,17 and in pa-
tients with end-stage renal disease.18 ACE inhibitors
have also been suggested, in studies using relatively
limited methods, to have more beneficial effects on
arterial stiffness—a variable that may influence the
load on the heart independently of mean blood pres-
sure—than other types of antihypertensive agents.19
However, few comparative studies of the cardiac ef-
fects of antihypertensive drugs have taken into ac-
count the potentially important effects on LV mass of
ambulatory blood pressure,20 arterial stiffness,18,21
and variations in stroke volume.18,22 Furthermore, the
relative impacts of antihypertensive agents on large
vessel hypertrophy in hypertension are unknown. Ac-
cordingly, the present study was undertaken to com-
pare the effects on cardiovascular structure of a rep-
resentative ACE inhibitor, ramipril, and of hydrochlo-
rothiazide, a prototypic diuretic.
METHODS
Study Design A screening echocardiogram was per-
formed at The New York Hospital—Cornell Medical
Center to verify that it was possible to obtain echocar-
diograms of sufficiently high quality in a participant
to be reproducible over time. In accord with our pre-
vious suggestion,23 individuals with elevated left ven-
tricular mass and ones with normal mass were both
included in the study. To prevent the expected reduc-
tion of initially high ventricular mass values over time
due to regression to the mean of qualifying measure-
ments that are required to exceed a predetermined
partition value,24 a separate baseline echocardiogram
was performed in all participants to document the
ability to obtain high-quality left ventricular images.
Eligible subjects underwent full evaluation including,
in addition to echocardiography, carotid ultrasonog-
raphy, 24-h ambulatory blood pressure determination,
and measurement of plasma renin activity, angioten-
sin II levels, and 24-h urinary sodium and albumin
excretion at baseline before beginning randomly as-
signed therapy, and after 3 and 6 months of treatment.
Study medication was begun at a dose of 5 mg
ramipril or 12.5 mg hydrochlorothiazide once a day. If
arterial pressure was not controlled (seated diastolic
blood pressure reduction by at least 7% and to a
level # 100 mm Hg), the blinded study medication
was doubled after 2 and 4 weeks to a maximum dose
of 20 mg/day ramipril or 50 mg/day hydrochlorothi-
azide.
Study Population Study subjects were recruited be-
tween June, 1993, and September, 1995, from a popu-
lation of employed adults enrolled in a worksite-based
hypertension detection and treatment program that
has been previously described.25,26 Eligibility criteria
included seated diastolic blood pressure of 95 to 114
mm Hg when not being treated or following a 4-week
placebo washout period. Of a total of 82 subjects who
underwent screening echocardiography, eight were
excluded because of technically limited echocardio-
grams, four were excluded because it was found after
the screening echocardiogram that they did not meet
other inclusion/exclusion criteria and three decided
that they did not want to enter the trial. An additional
seven patients in whom technically adequate echocar-
diograms showed normal left ventricular mass were
not enrolled in the study because the a priori target for
this study arm had already been achieved. Of the total
of 60 subjects enrolled in this randomized, double-
blind trial, seven were discontinued before the end of
the planned 6-month study duration because of inabil-
ity to control blood pressure by the maximum dose of
blinded study medication, two because of apparent
intolerance to study medication, and one because of
withdrawal of consent.
All patients were asymptomatic and free of clinical
evidence of cardiovascular disease other than hyper-
tension. In the 34 patients (68%) who had previously
received pharmacologic antihypertensive therapy,
medications were stopped for at least 4 weeks before
the baseline ambulatory monitoring and ultrasound
studies. Patients requiring other vasoactive medica-
tions were excluded from the study. Blood specimens
were obtained after an overnight fast, and serum lip-
ids and electrolytes were measured using standard
techniques. The study was performed using protocols
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approved by the Institutional Review Boards of Albert
Einstein College of Medicine and Cornell University
Medical College. All patients gave written, informed
consent to participate in the study.
Blood Pressure Determination Ambulatory blood
pressure recording was performed over a 24-h typical
day in all subjects using a SpaceLabs (Redmond, WA)
90207 monitor. As previously described,27 readings
were obtained every 15 min during the day and every
30 to 60 min at night. Patients were instructed to note
their activity in a diary. Blood pressure recordings
were classified according to activity using custom-
written software and averaged to reflect actual awake
and sleep periods. Basal blood pressure was defined
as that taken on the completion of the ultrasound
studies, ie, after approximately 1 h of supine rest in a
darkened, quiet room.
Echocardiography All echocardiograms were per-
formed by a single highly experienced research techni-
cian using standard techniques. Strip-chart recordings
were coded by the technician and measured by a single,
blinded observer using a digitizing tablet. Left ventricu-
lar dimensions were measured according to American
Society of Echocardiography recommendations.28 Left
ventricular mass (LVM) was calculated using the for-
mula: LVM 5 0.8 (1.04[LVIDd 1 IVSd 1 PWTd]
3 2
[LVIDd])
3 1 0.6 g, where LVID is left ventricular internal
dimension, PWT is posterior wall thickness, IVS is inter-
ventricular septal thickness and subscripted d indicates
end-diastole.29 Whenever the left ventricle was imaged
from too low a window to obtain optimal M-mode re-
cordings, ventricular measurements were obtained from
the two-dimensional study using American Society of
Echocardiography recommendations.30 Left ventricular
function was assessed by calculation of fractional short-
ening (FS): FS 5 (LVIDd 2 LVIDs)/LVIDd, where LVIDd
and LVIDs are end-diastolic and end-systolic diameters,
respectively. Left ventricular hypertrophy was consid-
ered to be present if the mass index exceeded 51 g/m2.7,
a partition value that may optimally predict cardiovas-
cular risk in hypertension.31 Left ventricular geometry
was classified using left ventricular mass index and rel-
ative wall thickness,32 using a relative wall thickness
partition value of 0.45. Stroke volume was calculated by
multiplying the time velocity integral of flow in the left
ventricular outflow tract by the area of the left ventricu-
lar outflow tract. Patients with valvular stenosis or more
than mild valvular regurgitation by Doppler echocardi-
ography were excluded from the study.
Carotid Ultrasonography Imaging of the right and
left extracranial carotid arteries was performed by the
same research technician using a 7.0 or 7.5 MHz trans-
ducer with the patient supine with slight hyperexten-
sion of the neck. The arteries were scanned for the
presence of discrete carotid atherosclerotic plaque.33
An M-mode tracing of the distal left common carotid
artery was recorded on videotape. Measurement of
the intimal-medial thickness of the far wall at end-
diastole and continuous tracing of the lumen-intima
interface of the near and far walls was performed
using a frame-grabber attached to a high resolution
monitor using previously described techniques.34,35
Measurements were performed on several cycles and
averaged. Wall thickness and lumen measurements
were never made at the level of a discrete plaque.
Arterial relative wall thickness (ARWT) was calcu-
lated as: ARWT 5 2 3 wall thickness/end-diastolic
diameter. Vascular strain (VS) was calculated accord-
ing to the formula: VS 5 (Ds 2 Dd)/Dd 3 100, where
Ds and Dd are common carotid artery peak-systolic
(maximum) and end-diastolic (minimum) diameters,
respectively. Supine brachial blood pressure was
taken in triplicate by the technician at the termination
of the ultrasound studies using an appropriately sized
cuff and mercury sphygmomanometer. These read-
ings were averaged to get the basal blood pressure.
Renin-Angiotensin System Assessment Twenty-
four hour urine collections were completed on the
morning the ultrasound studies were performed.
Plasma samples for determination of renin activity
and angiotensin II levels were obtained from previ-
ously ambulatory patients in the seated position. Mea-
surements of plasma renin activity and plasma angio-
tensin II levels were performed as previously de-
scribed.36,37 An HPLC step was included in the
angiotensin II assay prior to the radioimmunoassay.
Statistical Methods Data are presented as mean val-
ues with one standard deviation as the index of dis-
persion. Mean values in the two treatment groups
were compared using an independent-samples t test.
Categorical variables were compared using x2 analy-
sis. The relation of continuous variables was assessed
using linear regression (general linear model in SPSS
6, SPSS, Inc., Chicago, IL). Independent correlates of
the changes from baseline in left ventricular mass
were identified using multiple linear regression anal-
ysis with an enter procedure.
RESULTS
Baseline Characteristics A total of 50 patients com-
pleted the 6 month study. The 37 men and 13 women
had a mean age of 51.2 6 7.4 years (range 38 to 69).
Eighty-eight percent of the patients were nonwhite:
66% black (American or Caribbean), 18% Hispanic,
and 4% Asian Indian.
The 13 patients with and the 37 patients without left
ventricular hypertrophy did not differ with regard to
age, gender, race, body habitus, conventional labora-
tory parameters, or measures of the activity of the
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renin-angiotensin system. In contrast, the patients
with increased ventricular mass had higher basal
(159/98 v 146/93 mm Hg, P , .01 for systolic pres-
sure) and ambulatory blood pressure levels (24-h pres-
sure: 157/99 v 146/93 mm Hg, P , .05; awake pres-
sure: 160/101 v 149/96 mm Hg, P , .05). As expected,
all left ventricular dimensions, as well as calculated
ventricular mass (235.2 v 171.8 g) and mass indices
(58.4 v 39.5 g/ht2.7) were higher in the individuals
with left ventricular hypertrophy.
Randomized treatment assignment resulted in 28 of
the patients who completed the 6 month study receiv-
ing hydrochlorothiazide and 22 receiving ramipril. As
may be seen in Table 1, a higher proportion of the
ramipril-treated patients were women, as a conse-
quence of which body height, weight, and body sur-
face area—but not body mass index—were smaller in
this group. The levels of conventional laboratory vari-
ables and measures of renin-angiotensin system activ-
ity were statistically indistinguishable between these
groups. The patients assigned to receive ramipril had
slightly higher blood pressures than did those ran-
domized to the hydrochlorothiazide arm of the study,
but only the differences in sleep blood pressure
achieved statistical significance. The ramipril-treated
patients also had slightly, but generally insignifi-
cantly, higher levels for each of the primary left ven-
tricular measurements and calculated indices of ven-
tricular hypertrophy. The two groups did not differ in
vascular structure or function.
Effects on Renin-Angiotensin System Activity and
Blood Pressure As may be seen in Table 2, therapy
with hydrochlorothiazide resulted in a significant re-
duction in serum potassium and slight increases in
serum creatinine, glucose and total cholesterol concen-
trations, whereas these values remained stable in the
ramipril-treated patients. Treatment with ramipril re-
sulted in a significant and sustained reduction of
plasma angiotensin II levels and hydrochlorothiazide
caused a directionally opposite trend, with a highly
significant between-groups difference by repeated
measures analysis of variance, whereas both agents
caused similar increases in plasma renin activity.
Highly significant decreases in arterial pressure ob-
tained at the completion of the ultrasound studies (basal
blood pressure) occurred in the diuretic-treated patients
but not in those who received ramipril. In contrast, both
24-h and day and night systolic and diastolic pressures
were significantly reduced by ramipril, but fell even
more in hydrochlorothiazide-treated patients. Further-
more, the percent change in the 24-h ambulatory blood
pressure was significantly greater in the hydrochlorothi-
azide-treated group (24-h pressure: 29.1/29.1% v 23.2/
24.4%, P , .05).
TABLE 1. COMPARISON OF BASELINE CHARACTERISTICS OF PATIENTS TREATED
WITH RAMIPRIL VERSUS HYDROCHLOROTHIAZIDE
Variable Ramipril (n 5 22) P Hydrochlorothiazide (n 5 28)
Age (years) 52.7 6 6.9 NS 50.1 6 7.7
Gender (% male) 59 ,.05 86
Race (% nonwhite) 91 NS 86
Height (in.) 65.6 6 4.3 ,.01 68.6 6 3.0
Weight (lb.) 171.5 6 33.1 NS 186.0 6 30.9
Body surface area (m2) 1.86 6 0.23 ,.05 1.99 6 0.19
Body mass index (kg/m2) 27.8 6 3.0 NS 27.7 6 3.6
Basal blood pressure (mm Hg) 153/94 NS 146/95
24-h blood pressure (mm Hg) 153/96 NS 146/93
Awake blood pressure (mm Hg) 155/98 NS 149/96
Sleep blood pressure (mm Hg) 142/87 ,.05 134/82
Left ventricular
Septum (cm) 1.09 6 0.12 NS 1.05 6 0.16
Posterior wall (cm) 0.99 6 0.11 NS 0.96 6 0.13
Diastolic diameter (cm) 5.00 6 0.51 NS 5.00 6 0.42
Mass (g) 193.5 6 46.6 NS 184.4 6 42.4
Mass index (g/m2) 103.6 6 20.3 NS 92.7 6 19.9
Mass/height2.7 (g/m2.7) 48.5 6 10.2 ,.01 41.1 6 9.0
Fractional shortening (%) 37 6 8 NS 36 6 6
Common carotid artery
Intimal-medial thickness (mm) 0.77 6 0.14 NS 0.75 6 0.15
Cross-sectional area (mm2) 15.6 6 4.3 NS 15.4 6 3.9
Strain (%) 12.1 6 2.9 NS 11.0 6 3.4
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Effects on the Left Ventricle and Common Carotid
Artery There were small decreases in left ventricular
wall thickness and mass during hydrochlorothiazide
treatment that did not attain statistical significance (Ta-
ble 3). In contrast, decreases in left ventricular wall thick-
ness, but not in chamber size, resulted in substantial
reductions in left ventricular mass in the ramipril-treated
patients after 3 and 6 months of taking the study medi-
cation (Figure 1). The strongest univariate correlates of
the percent change in left ventricular mass were the
percent change in basal systolic (r 5 0.47, P , .0005) and
diastolic (r 5 0.44, P 5 .001) blood pressures and the
initial level of left ventricular mass (r 5 20.30, P , .05).
In multivariate analyses, the change in left ventricular
mass was predicted by the change in either basal systolic
or diastolic blood pressure (P , .0005 for both), and
independently by the assigned treatment group (P 5
.05). There were no changes in left ventricular stroke
volume in either group.
Although there were no significant changes associated
with either drug in carotid artery size or vascular strain,
relative wall thickness of the vessel significantly in-
creased in the diuretic-treated group due to a strong
tendency for vessel diameter to decrease and wall thick-
ness to increase (Figure 2). Arterial cross-sectional area
tended to increase in both drug groups, although the
changes did not achieve statistical significance.
DISCUSSION
In the present study, short-term antihypertensive ther-
apy with an ACE inhibitor and suppression of angio-
tensin II levels resulted in a marked reduction in left
ventricular mass during short-term therapy due to a
decrease in wall thicknesses. In contrast, significantly
TABLE 2. IMPACT OF DRUG THERAPY ON RENIN-ANGIOTENSIN SYSTEM AND BLOOD PRESSURE
Variable
Ramipril Hydrochlorothiazide
Baseline 3 month 6 month P Baseline 3 month 6 month P
Sodium (mEq/L) 141.2 6 2.5 141.1 6 2.5 141 6 2.3 NS 140.2 6 1.3 140.1 6 1.5 140.0 6 1.5 NS
Potassium (mEq/L) 4.16 6 0.35 4.22 6 0.27 4.22 6 0.29 NS 4.20 6 0.38 3.87 6 0.53 3.87 6 0.40 ,.005
Creatinine (mg/dL) 1.06 6 0.25 1.05 6 0.20 1.09 6 0.27 NS 1.11 6 0.20 1.15 6 0.19 1.19 6 0.23 ,.05
Glucose (mg/dL) 92.1 6 9.6 96.5 6 16.9 97.3 6 12.0 NS 90.4 6 11.6 88.4 6 15.2 98.7 6 21.4 NS (.06)
Cholesterol (mg/dL) 211 6 30 217 6 37 218 6 31 NS 201 6 37 211 6 36 215 6 38 ,.05
PRA (ng AI/mL/h) 0.96 6 1.50 1.98 6 3.07 2.04 6 2.51 ,.01 0.73 6 0.92 2.06 6 2.08 1.51 6 1.75 ,.005
Angiotensin II (ng/mL) 2.26 6 3.94 0.96 6 2.36 0.84 6 1.41 ,.05 2.20 6 3.06 5.65 6 7.22 4.42 6 6.90 NS (.06)
Basal BP (mm Hg) 153/94 148/90 147/91 NS 146/95 136/90 136/88 ,.001
24-h BP (mm Hg) 153/96 144/89 147/91 ,.001 146/93 136/86 132/84 ,.001
Awake BP (mm Hg) 155/98 147/92 150/94 ,.005 149/96 139/90 136/88 ,.001
Sleep BP (mm Hg) 142/87 133/81 136/82 ,.01 134/82 123/75 121/74 ,.001
PRA, plasma renin activity; BP, blood pressure.
TABLE 3. IMPACT OF DRUG THERAPY ON LEFT VENTRICLE AND CAROTID ARTERY
Variable
Ramipril Hydrochlorothiazide
Baseline 3 month 6 month P Baseline 3 month 6 month P
Left ventricular
Septum (cm) 1.09 6 0.12 1.00 6 0.12 1.04 6 0.13 ,.05 1.06 6 0.16 1.03 6 0.13 1.02 6 0.10 NS
Posterior wall (cm) 0.99 6 0.11 0.90 6 0.12 0.93 6 0.12 ,.05 0.96 6 0.13 0.94 6 0.11 0.93 6 0.16 NS
Diastolic diameter (cm) 5.00 6 0.51 5.02 6 0.63 4.98 6 0.55 NS 5.00 6 0.42 4.99 6 0.41 5.07 6 0.47 NS
Mass (g) 193.2 6 46.6 172.5 6 45.5 179.1 6 47.9 ,.005 184.4 6 42.4 178.3 6 38.0 181.8 6 47.1 NS
Mass index (g/m2) 103.6 6 20.3 92.0 6 18.9 94.9 6 19.9 ,.001 92.7 6 19.9 90.9 6 19.4 91.9 6 23.3 NS
Mass/height2.7 (g/m2.7) 48.5 6 10.2 43.2 6 9.2 44.8 6 9.5 ,.005 41.1 6 9.0 40.0 6 8.85 40.9 6 11.6 NS
Stroke volume (mL) 67.6 6 14.4 66.4 6 11.2 67.3 6 15.3 NS 72.2 6 12.2 71.6 6 12.5 74.8 6 17.9 NS
Common carotid artery
IMT (mm) 0.77 6 0.14 0.77 6 0.18 0.82 6 0.13 NS 0.75 6 0.15 0.83 6 0.17 0.83 6 0.24 NS
Diastolic diameter (mm) 5.61 6 0.73 5.67 6 0.61 5.58 6 0.61 NS 5.74 6 0.70 5.53 6 0.65 5.56 6 0.75 NS
CSA (mm2) 15.6 6 4.3 15.9 6 4.1 16.6 6 3.6 NS 15.4 6 3.9 16.6 6 4.5 17.0 6 6.1 NS
Relative wall thickness 0.28 6 0.05 0.28 6 0.08 0.30 6 0.05 NS 0.27 6 0.06 0.30 6 0.06 0.30 6 0.09 ,.05
Strain (%) 12.1 6 2.9 12.3 6 4.9 12.8 6 4.4 NS 11.0 6 3.4 12.0 6 3.4 11.6 6 3.3 NS
IMT, intimal-medial thickness; CSA, cross-sectional area.
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FIGURE 1. Impact of drug therapy on left ventricular wall thicknesses, chamber size and mass. HCTZ, hydrochlorothiazide.
FIGURE 2. Impact of drug therapy on carotid artery structure. HCTZ, hydrochlorothiazide.
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greater (P , .05) lowering of 24-h ambulatory blood
pressure with a diuretic resulted in no change in left
ventricular mass. Neither class of antihypertensive
therapy reduced vascular size. In fact, arterial cross-
sectional area, a measure of vascular mass, tended to
increase in both treatment groups due to slight in-
creases in vessel wall thickness. A significant increase
in vascular relative wall thickness (concentric remod-
elling) developed in the diuretic group. Our study
supports the importance of the trophic influence of
angiotensin II on cardiac myocytes and suggests that
hemodynamic factors may be of greater relevance in
determining changes in vascular structure.
The finding with regard to left ventricular mass is in
keeping with two previous metaanalyses indicating
that the greatest reduction in left ventricular mass was
associated with ACE inhibitor therapy.12,14 While the
magnitude of decrease in left ventricular mass with
ramipril (7.3%) and hydrochlorothiazide (1.3%) was
lower than previously detected on average in other
randomized, double-blind studies (13.5% with ACE
inhibitors and 7.8% with diuretics14), the extent of
blood pressure lowering was also less in the current
study.
The use of ambulatory, rather than clinic, blood
pressure in the current study increased the accuracy of
determination of overall hemodynamic burden and its
relation to left ventricular mass.20 Although the im-
portance of blood pressure reduction in determining
the extent of regression of left ventricular mass was
confirmed in the present study, the study clearly doc-
umented that factors other than blood pressure influ-
ence the degree to which left ventricular mass is re-
duced. In a metaanalysis confined to randomized,
double-blind studies, Schmieder et al found that, in
addition to the extent of blood pressure lowering,
duration of antihypertensive therapy and degree of
pretreatment left ventricular hypertrophy were di-
rectly related to magnitude of regression.14 The latter
observation was also confirmed by univariate analysis
in the present study, although in multivariate analyses
initial left ventricular mass was not an independent
predictor of the extent of regression.
Similar to the results of the present study, the meta-
analysis by Schmieder et al14 also found that drug
class was important in the extent of regression of left
ventricular mass, with ACE inhibitors being signifi-
cantly better than b-blockers and tending to be better
than diuretics (P 5 .08) and calcium channel blockers
(P 5 .12), whereas the latter three drug classes were
equally efficacious. The recently reported Veterans
Administration monotherapy trial found that the
greatest reduction in left ventricular mass, after con-
trol for appropriate covariates, was achieved by an
ACE inhibitor and a diuretic, with lesser effects of the
studied calcium blocker and b-blocker.38 The lack of a
greater effect on ventricular mass by the ACE inhibitor
might have been due to use of a short-acting ACE
inhibitor (captopril) on a twice-a-day schedule. The
apparent superiority of a diuretic in the Treatment of
Mild Hypertension Study39 is difficult to interpret be-
cause the groups assigned to placebo pills became
normotensive (mean blood pressure 5 133/82 mm
Hg) with very normal ventricular mass (mean 5
178 g), leaving neither hypertension nor left ventricu-
lar hypertrophy for the drugs to treat.
The mechanism underlying the apparent greater
magnitude of left ventricular regression with ACE
inhibition in comparison to other drug classes is not
entirely clear. In some animal studies, doses of
ramipril that did not significantly lower blood pres-
sure under anesthesia in rats with suprarenal aortic
banding16 or pulmonary artery banding40 resulted in
the prevention or reversal of cardiac hypertrophy.
However a subsequent study suggested that blood
pressure lowering was necessary for the beneficial
effect of ramipril on left ventricular mass.17 Although
the addition of 1.25 or 5 mg ramipril to 20 mg furo-
semide in human hypertensives resulted in a greater
decrease in left ventricular mass than placebo added
to furosemide, the addition of ramipril tended to cause
greater blood pressure lowering, which may have in-
fluenced study findings.15 The extent to which a pres-
sure-independent mechanism of ACE inhibition of re-
ducing vascular hypertrophy or left ventricular mass
relates to antagonism of direct trophic effects of an-
giotensin II on vascular smooth muscle or cardiac
myocytes, detected in experimental models,41,42 is un-
certain.
The association of hypertension with hypertrophy
of the capacitance, as opposed to resistance, vessels is
well-established, and recent advances in noninvasive
imaging technology have permitted in vivo quantifi-
cation of its nature and extent in controlled stud-
ies.34,35,43,44 In addition, increased plasma ACE activ-
ity45 and certain ACE gene polymorphisms46 have
been associated with hypertrophy of the common ca-
rotid artery independently of blood pressure. Al-
though numerous studies have evaluated the impact
of antihypertensive therapy on the functional charac-
teristics of the capacitance vessels, such as vascular
compliance, information regarding the impact of ther-
apy on structural changes in these large arteries in
humans is lacking. In spontaneously hypertensive
rats, both calcium channel blockers47,48 and ACE in-
hibitors have been effective in reducing vascular hy-
pertrophy, whereas vasodilators and b-blockers have
not.49 In the present study, neither form of antihyper-
tensive therapy resulted in a change in overall vessel
size (cross-sectional area), but vascular remodeling
with increased relative wall thickness, which achieved
statistical significance in the diuretic-treated group,
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occurred as a consequence of the tendency for vessel
diameter to decrease and intimal-medial thickness to
increase.
The response of the capacitance vasculature to
blood pressure reduction may be variable and unpre-
dictable. Large vessel hypertrophy in hypertension
appears to occur as a consequence of both an increase
in vessel diameter and in wall thickness.35 Whether
the increase in wall thickness reflects ‘‘early athero-
sclerosis’’ due to intimal thickening or an increase in
smooth muscle mass resulting in medial hypertrophy,
or a combination of both processes, is unknown and
may vary among individuals. By conservation of
mass, a reduction in the distending pressure by any
antihypertensive medication may acutely cause the
vessel diameter to decrease and the wall thickness to
increase. Alternatively, medications that specifically
relax smooth muscle cells may result in an increase in
vessel diameter and a decrease in wall thickness but
no change in cross-sectional area. The findings in the
current study are consistent with the former mecha-
nism and underscore the need to consider both wall
thickness and vessel diameter in assessing the impact
of interventions. Thus the results of the recent Multi-
center Isradipine Diuretic Atherosclerosis Study (MI-
DAS), wherein both a diuretic and a dihydropyridine
calcium channel blocker resulted in similar progres-
sion of the mean maximum carotid intimal-medial
thickness and of ‘‘normal segments’’ (comparable to
those evaluated in the present study), despite signifi-
cant blood pressure reduction, may reflect remodeling
of the arteries in response to successful blood pressure
lowering as opposed to progressive ‘‘early atheroscle-
rosis.’’50
Study Limitations Although the study population is
relatively small, it constitutes one of the largest groups
treated with ramipril as monotherapy in a double-
blind randomized trial.14 The duration of therapy was
short, but was adequate in this and in a previous
study51 to show highly significant differences between
ACE inhibition and a diuretic in changes in left ven-
tricular mass. Hemodynamic load was assessed by
measurement of both basal blood pressure and ambu-
latory blood pressure in the brachial artery; however,
brachial blood pressure may differ from central aortic
pressure to a variable extent. Furthermore changes in
brachial blood pressure with pharmacologic therapy
may not necessarily be indicative of changes in central
aortic pressure or of the impact of therapy on the
timing of reflected waves and thereby changes in aug-
mentation of the pressure waveform.21 Finally, the
extent to which the ethnic characteristics of this largely
nonwhite population influenced results is unknown in
the absence of other data indicating racial differences
in the effectiveness of antihypertensive therapy in in-
ducing regression of left ventricular hypertrophy.
In conclusion, the observed greater reduction in left
ventricular mass associated with ACE inhibition in the
current study and other studies and experimental data
linking angiotensin II to myocardial growth, com-
bined with the strong association of left ventricular
mass with cardiovascular risk, may provide a patho-
physiologic explanation for the ability of the renin
profile to predict myocardial infarction in hyperten-
sive patients.4–6 Greater reduction of left ventricular
mass may result in a more conclusive reduction in the
cardiac complications of hypertension over the long
term, particularly in view of preliminary evidence
suggesting that reversal of left ventricular hypertro-
phy results in a reduction in cardiovascular events.52
The impact of antihypertensive therapy on the hyper-
trophy of large vessels in human hypertensives re-
mains uncertain. However, the results of the present
study suggest that these arteries may show less true
regression than does the left ventricle in response to
relatively short-term blood pressure lowering.
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